Get the Stockscreener App
1.12
1.82%
0.02
Artelo Biosciences Inc stock is traded at $1.12, with a volume of 13,992.
It is up +1.82% in the last 24 hours and up +12.00% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.10
Open:
$1.09
24h Volume:
13,992
Relative Volume:
0.04
Market Cap:
$3.45M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.3544
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
+6.67%
1M Performance:
+12.00%
6M Performance:
-8.65%
1Y Performance:
-21.68%
1-Day Range:
$1.0875
$1.12
1-Week Range:
$1.01
$1.13
52-Week Range:
$0.8196
$1.55
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.12 | 3.45M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences (NASDAQ:ARTL) Receives “Buy” Rating from D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Receives Continued 'Buy' Rating from D. Boral Capital | ARTL Stock News - GuruFocus
Artelo Biosciences presents promising OA pain treatment data By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) Highlights New FABP Inhibitor Data at British Pain Conference | ARTL Stock News - GuruFocus
Artelo Biosciences presents promising OA pain treatment data - Investing.com
Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - Yahoo Finance
Artelo Biosciences (NASDAQ:ARTL) Stock Price Down 3.7% – Should You Sell? - Defense World
ARTL: Potential of Fabp Inhibitors in Treating Mood Disorders Hi - GuruFocus
Independent Study Confirms Breakthrough Potential of Artelo's Novel Anxiety DrugPhase 1 Data Coming - Stock Titan
Artelo Biosciences Reports Q1 2025 Financial Results - TipRanks
Artelo Biosciences Faces Nasdaq Compliance Challenge - TipRanks
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday - Defense World
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Reports Promising Psoriasis Treatment Advances | ARTL Stock News - GuruFocus
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models - AOL.com
Artelo Biosciences Announces Publication of New Peer-Reviewed Re - GuruFocus
Artelo Biosciences Reports Positive Effects Of ART26.12 In Psoriasis Models - Nasdaq
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis - The Manila Times
Artelo Biosciences Announces Positive Preclinical Results for Psoriasis Treatment ART26.12 in Journal of Investigative Dermatology - Nasdaq
Breakthrough Oral Psoriasis Treatment Matches Current Drugs in New Research, Phase 1 Results Coming - Stock Titan
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Grows By 58,220.0% - Defense World
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ARTL stock touches 52-week low at $0.85 amid market challenges - Investing.com
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Artelo Biosciences stock hits 52-week low at $0.91 - Investing.com
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - The Manila Times
New Data Reveals Artelo's FABP5 Inhibitor Could Transform Pain and Cancer Treatment - Stock Titan
Artelo Biosciences (ARTL) Projected to Post Earnings on Monday - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
HC Wainwright Has Pessimistic View of ARTL FY2025 Earnings - Defense World
Artelo Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright - Defense World
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - The Manila Times
ARTELO BIOSCIENCES, INC. SEC 10-K Report - TradingView
Can Artelo's Three Clinical Programs Overcome Its $9.8M Annual Loss? - StockTitan
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Increase in Short Interest - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Artelo Biosciences reports promising nonclinical CBD study - MSN
Analyzing Artelo Biosciences (NASDAQ:ARTL) & Rafael (NYSE:RFL) - Defense World
Artelo Biosciences Reports Positive ART12.11 Tablet Data Showing Improved Pharmacokinetics - Nasdaq
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - GlobeNewswire
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):